US Pharmaceutical Excipients Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 3.08 Bn

Forecast Year, 2035

USD 5.58 Bn

CAGR, 2026 - 2035

6.12%

Report Coverage

U.S.

US Pharmaceutical Excipients Market Size and Forecast 2026 to 2035

The US pharmaceutical excipients market size accounted for USD 3.08 billion in 2025 and is predicted to increase from USD 3.28 billion in 2026 to approximately USD 5.58 billion by 2035, expanding at a CAGR of 6.12% from 2026 to 2035. The market growth is attributed to rising demand for biologics, specialty drugs, and advanced pharmaceutical formulations requiring high-performance excipients.

Key Takeaways

• By functionality, the fillers and diluents segment held the largest market share in 2025.
• By functionality, the coating agents segment is expected to expand significantly during the forecast period.
• By excipient type, the lactose-based excipients segment held the largest share of the market in 2025.
• By excipient type, the cellulose-based segment is expected to grow with a significant CAGR between 2026 and 2035.

Market Overview

The U.S. pharmaceutical excipients market is driven by rising demand for advanced drug formulations, biologics, and patient-friendly dosage forms. Pharmaceutical excipients are inert ingredients that are added to drugs to promote stability, bioavailability, manufacturability, and therapeutic activity. Excipients can make up to 90% of the formulation of a medicine, highlighting their importance in the manufacture of medicines in the United States Pharmacopeia (USP).

The identification of multifunctional excipients is continuing to increase in demand due to the increasing development of complex oral drug formulations, injectables, and biologic-based drugs. These materials are useful to achieve consistency in formulations for manufacturing and have set high-quality and regulatory requirements. Furthermore, the expanding biologics development and increasing adoption of innovative drug delivery technologies continue to drive market growth.

Impact of Artificial Intelligence on the U.S. Pharmaceutical Excipients Market

Artificial intelligence (AI) is transforming the market by speeding up the selection of excipients and product development efforts. AI-based models are increasingly used in the drug manufacturing industry to assess the effect of excipients on the stability, solubility, dissolution rates, and bioavailability of a drug.

These technologies aid formulation scientists in finding the right combination of excipients and minimizing the number of iterations in the lab. AI can also aid in sophisticated manufacturing process monitoring, identifying deviations in manufacturing processes before product quality is compromised.

Market Report Coverage and Key Metrics

Market Dynamics

Drivers

Growing Demand for Advanced Drug Formulations and Biologics

Growing demand for advanced drug formulations and biologic therapies is projected to accelerate market growth in the coming years. The increase in demand for sophisticated drug formulations and biologic products is expected to drive excipient consumption in the pharmaceutical production processes. Furthermore, the rising adoption of novel drug delivery technologies is expected to increase the utilization of functional excipients throughout pharmaceutical product development.

Restraint

Stringent Regulatory and Quality Compliance Requirements

Expansion through stringent regulatory and quality compliance requirements is expected to hinder the market growth. Complying with numerous regulations creates higher financial and operational costs and stresses it even more for smaller manufacturers. Moreover, the dependence on complex global raw material supply chains is anticipated to create procurement and production challenges, thus restraining market growth.

Opportunity

Surging Implementation of Continuous Pharmaceutical Manufacturing

Surging implementation of continuous pharmaceutical manufacturing is likely to create immense opportunities for players competing in the market. Continuous pharmaceutical manufacturing gains traction, accelerating the usage of excipients that can deliver robust performance and processing efficiency. Additionally, increasing investments in digital manufacturing technologies and process optimization efforts are further driving the need for high purity of excipients selection.

Market Segmentation Analysis

Functionality Insights

The Fillers and Diluents Segment Dominated the Market in 2025

The fillers and diluents segment dominated the market in 2025 due to their essential role in nearly every solid oral dosage formulation. Such ingredients play an indispensable role in the manufacture of pharmaceutical tablets. This ensures uniformity of weight, dosage uniformity, and the ability to produce in large quantities.

Lactose, microcrystalline cellulose, and mannitol are still used in a variety of prescription and non-prescription medications. The long history of use and regulatory acceptance assures wide use, particularly in commercial manufacturing facilities. Demand for cost-effective formulation components was further bolstered by the rising demand for the growth of production of generic drugs by firms across the U.S.

The coating agents segment is expected to grow at a significant CAGR from 2026 to 2035, owing to the pharmaceutical industry's increasing focus on advanced dosage performance and patient experience. Coating technologies are now increasingly being used by drug manufacturers to enhance the stability of the product. This protects it from moisture, masks the taste, and aids in swallowing the drug. Moreover, the Increased development of differentiated drug products is expected to further drive the use of advanced coating technologies.

Excipient Type Insights

The Lactose-based Excipients Segment Dominated the Market in 2025

The lactose-based excipients segment dominated the market in 2025, as they have excellent compressibility and formulation versatility. Lactose is in great demand as a tablet and capsule excipient, dry powder inhaler dosage form, and as an excipient in combination drug products for pharmaceutical production.

It has good flow properties, enabling efficient mass production in large commercial production facilities at high speeds. The ingredient is also found to be highly compatible with many other ingredients for use in generic and branded drugs. Pharmaceutical-grade lactose availability in North America has improved in recent years due to large-scale expansion by firms like DFE Pharma and MEGGLE Pharma.

DFE Pharma launched a project in 2026 to promote sustainability called EcoLact 2030, encompassing its portfolio of lactose products and offering verified value chain traceability. The company claimed that alongside this portfolio, COâ‚‚ emissions are 30% lower for the accelerated change, but pharmaceutical quality and regulatory compliance are maintained. The development is a continuation of the innovations and investments in lactose-based excipient production.

The cellulose-based excipients segment is expected to grow at a significant CAGR between 2026 and 2035, due to the expanding pipeline of complex drug products. Cellulose-based materials are anticipated to experience strong future demand. Manufacturers are using microcrystalline cellulose and derivatives to harden, improve uniformity, and improve tablet processing.

They are materials used to bind, fill, and disintegrate, which simplify the formulation process in product development. The high demand for high-performance excipients for specialty medicines has boosted interest in advanced cellulose technologies. These attributes are expected to enable continued growth during the next decade in the ongoing pharmaceutical development and commercialization programs.

U.S. Therapeutic Neurotoxin Market: Country-Level Analysis

Why is New Jersey Leading the U.S. Pharmaceutical Excipients Market?

New Jersey leads the market in the U.S., due to the presence of concentrated pharmaceutical manufacturing and research settings in the state. The state has a good number of Contract Development Organizations, Formulation Technology Development Organizations (FTDO), with extensive operations that need a significant volume of pharmaceutical excipients. Pharmaceutical companies are still investing in production modernization, quality systems, and advanced product development programs, which are driving the demand for high-performance excipient materials.

U.S. Pharmaceutical Excipients Market Value Chain Analysis

• Raw Material Sourcing

Natural, synthetic, and semi-synthetic materials are sourced for pharmaceutical excipient production.

Key Players: Ashland, Roquette, BASF, Croda International.

• Excipient Manufacturing & Processing

Raw materials are processed into pharmaceutical-grade excipients under strict quality standards.

Key Players: DFE Pharma, JRS Pharma, MEGGLE Pharma, Evonik.

• Formulation Integration & Quality Testing

Excipients undergo performance testing before integration into pharmaceutical formulations.

Key Players: Colorcon, Lubrizol Life Science Health, SPI Pharma, Roquette.

• Pharmaceutical Manufacturing & Distribution

Finished excipients are supplied to drug manufacturers for commercial pharmaceutical production.

Key Players: Pfizer, Eli Lilly, Johnson & Johnson, Thermo Fisher Scientific.

Market Competitive Landscape: Leading Companies and Strategies

The U.S. pharmaceutical excipients market remains moderately consolidated among global specialty ingredient suppliers. Ashland, Roquette, BASF Pharma Solutions, and Evonik are well-positioned in their respective industries. DFE Pharma and MEGGLE Pharma are moving forward in increasing their pharmaceutical Lactose capabilities worldwide. There is a growing number of suppliers that can provide products for niche applications that have specific characteristics for formulation performance. High qualification requirements create significant barriers for newly entering manufacturers.

Recent competitive activity is an indicator of higher levels of innovation and manufacturing network investment. Roquette's 2025 product expansion was in the area of pharmaceutical coating technology for oral formulations. Advanced formulation technology investments boosted Evonik's drug delivery competencies. The digital formulation tool market is becoming integrated into companies to speed up development programs.

U.S. Pharmaceutical Excipients Market Companies

• BASF SE
• Ashland Global Holdings Inc.
• DuPont de Nemours Inc.
• Roquette Frères SA
• Evonik Industries AG
• Archer Daniels Midland Co.
• Kerry Group plc
• The Lubrizol Corporation
• Air Liquide SA
• Croda International plc
• Innophos Holdings Inc.
• Colorcon Inc.
• DFE Pharma GmbH & Co. KG
• JRS Pharma GmbH & Co. KG
• Eastman Chemical Company
• International Flavors & Fragrances Inc.
• Merck KGaA
• Dow Inc.
• Gattefossé SA
• Shin-Etsu Chemical Co. Ltd.

Recent Developments

• In May 2026, Novartis will open a new facility in Morrisville, North Carolina, dedicated to the manufacturing of active pharmaceutical ingredients (APIs) for solid dosage forms such as tablets, capsules, and RNA therapeutics. With this addition, Novartis will expand its presence in North Carolina to five facilities across three sites.
• In May 2026, CordenPharma, a leading global CDMO, announced that it had agreed to acquire AmbioPharm, a U.S.-based peptide API CDMO. AmbioPharm operates two sites, one in South Carolina and another in Shanghai, China. The acquisition will enhance CordenPharma's Peptides Platform by adding differentiated peptide manufacturing capabilities. This acquisition will provide customers with flexible options tailored to their specific manufacturing needs for complex, long, and high-purity peptide APIs.

Segments Covered in the Report

By Functionality

• Fillers and Diluents
• Suspending and Viscosity Agents
• Coating Agents
• Binders
• Disintegrants
• Colorants
• Lubricants and Glidants
• Preservatives
• Emulsifying Agents
• Flavoring Agents and Sweeteners
• Other Functionalities

By Excipient Type

• Lactose-based Excipients
  • α-lactose monohydrate
  • Anhydrous α-lactose
  • Anhydrous β-lactose
  • Amorphous Lactose
• Cellulose-based
  • Microcrystalline Cellulose (MCC)
  • Cellulose Ethers
  • Others
• Starches
• Carboxymethylcellulose Sodium (CCS)
• Sodium Starch Glycolate (SSG)
• Fine Chemicals
• Mannitol
• Biopharma Excipients
• Others